Hycor Biomedical Test Kit Gets FDA Nod
- Share via
Hycor Biomedical Inc., a Garden Grove maker of medical diagnostic products, said Tuesday that it has received clearance from the U.S. Food and Drug Administration to market its newest autoimmune test kit in the United States.
Hycor said the kit, called Anti-Cardiolipin IgM ELISA, detects the presence of antibodies associated with anti-phospholipid syndrome. These antibodies can cause clotting problems and low platelet counts in patients with autoimmune disease.
The company said the product complements its previously cleared Anti-Cardiolipin IgG autoimmune kit. Hycor intends for the tests to replace older manual methodologies.
Hycor’s stock closed Tuesday at $2.13 a share, up 13 cents in Nasdaq trading.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
